Kevin J Tidgewell

US Patent:

20130045925, Feb 21, 2013

Filed:

Mar 11, 2011

Appl. No.:

13/581288

Inventors:

William H. Gerwick - La Jolla CA, US
Kevin Tidgewell - Pittsburgh PA, US
Frederick A. Valeriote - Detroit MI, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 38/07
C12N 5/071
A61P 35/04
A61P 29/00
C07K 5/10
A61P 35/00

US Classification:

514 198, 530323, 514 192, 514 199, 514 211, 435375

Abstract:

In alternative embodiments, the invention provides apratoxin F and apratoxin G compounds, which include apratoxin F and apratoxin G stereoisomers, derivatives and analogs compositions and methods. In alternative embodiments, the invention provides pharmaceutical compositions and formulations comprising apratoxin F (compound 6 of FIG. ) and apratoxin G (compound 7 of FIG. ) and their stereoisomers, derivatives and analogs. In alternative embodiments, pharmaceutical compositions and formulations of the invention are administered in an amount sufficient to treat, prevent and/or ameliorate a disease or condition that can be ameliorated by decreasing or inhibiting cell growth, e.g., pathological, uncontrolled or unwanted cell growth, e.g., a cancer or a metastases, or any disease or condition (e.g., allergy) or infection having a hyperproliferative cell growth component.